# LET'S GET "REAL" MINIMIZING ALLOGRAFT REJECTION IN RENAL TRANSPLANTATION:

Applying the Evidence to Real-World Scenarios

## VIRTUAL SATELLITE SYMPOSIUM

## **SUNDAY, JUNE 6, 2021**

1:30 рм - 2:30 рм edt

**PROGRAM CHAIR** Daniel Brennan, MD

For more information, visit us at...





**STAY CONNECTED!** Follow us @GoToPER and share your thoughts by using #gotoper.

## Welcome

Dear Colleague:

On behalf of Physicians' Education Resource<sup>®</sup>, LLC (PER<sup>®</sup>), we would like to welcome you and thank you for choosing to attend Let's Get "Real": Minimizing Allograft Rejection in Renal Transplantation – Applying the Evidence to Real-World Scenarios.

Renal transplantation is an effective treatment option for patients with end-stage renal disease. Long-term survival of the transplant can be affected by rejection. Sensitization to human leukocyte antigens (HLAs) can be a significant obstacle to kidney transplantation. Desensitization is one of the recommended options to increase the chance of achieving transplantation for HLA-sensitized patients.

Desensitization protocols are becoming further refined, new drugs are being developed and organ allocation policies are changing. Nevertheless, the problem of donor-specific antibodies remains incompletely solved and many patients remain poorly served by the therapies that do exist.

This activity will provide clinicians with insights into the different mechanisms of allograft rejection that may be therapeutic targets for prevention. It will also help familiarize them with current and emerging therapies used in desensitization protocols to increase the chance of achieving transplantation for highly sensitized patients.

In working together with PER<sup>®</sup>, we strive to make this activity, along with all PER<sup>®</sup> accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with renal transplantation.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of renal transplantation. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER<sup>®</sup> virtual symposium and that you can attend another PER<sup>®</sup> accredited CE activity soon.

Regards,

#### Daniel Brennan, MD

Medical Director, Comprehensive Transplant Center Professor of Medicine Johns Hopkins Medicine Baltimore, MD

Phil Talamo, CHCP President Physicians' Education Resource<sup>®</sup>, LLC Cranbury, NJ ptalamo@gotoper.com

## Agenda

1:30 рм	Welcome and Introductions	Daniel Brennan, MD
1:35 рм	Pathophysiology and Mechanisms of Allograft Rejection	Daniel Brennan, MD; Rita R. Alloway, PharmD; E. Steve Woodle, MD
1:40 рм	HLA Sensitivity and Desensitization Protocols	Daniel Brennan, MD; Rita R. Alloway, PharmD; E. Steve Woodle, MD
1:55 рм	Ensuring Transplantation Success in Patients with Risk Factors for HLA-Sensitivity	Daniel Brennan, MD; Rita R. Alloway, PharmD; E. Steve Woodle, MD
2:05 рм	Strategizing Care for a Patient with HLA-Sensitivity who Inadequately Responds to Initial Desensitization	Daniel Brennan, MD; Rita R. Alloway, PharmD; E. Steve Woodle, MD
2:15 рм	Integrating the Evidence to Optimize Care for a Post-Renal Transplantation Patient	Daniel Brennan, MD; Rita R. Alloway, PharmD; E. Steve Woodle, MD
2:25 рм	Conclusions	Daniel Brennan, MD
2:30 рм	Adjourn	

Upcoming PER <sup>®</sup> Conferences	2021
2nd Annual Live Medical Crossfire <sup>®</sup> : IBS and IBD - Virtual Conference	Saturday, June 5
5th Annual Live Medical Crossfire <sup>®</sup> : Hematologic Malignancies - Virtual Conference	Saturday, July 17
2nd Annual International Congress on the Future of Women's Health™ - Virtual Conference	Saturday, July 24
4th Annual Advanced Practice Collaborative	Saturday, September 11
3rd Annual International Congress on the Future of Neurology®	September 17 - 18
5th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)	Saturday, September 18

## **Activity Overview**

### **Target Audience**

This educational activity is directed toward for transplant specialists, transplant surgeons, and nephrologists. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of renal transplantation patients will also be invited to participate.

### **Learning Objectives**

At the conclusion of this activity, you should be better prepared to:

- Review mechanisms of renal transplant rejection that may offer targets for therapy
- Develop management plans using current and emerging therapies for desensitization of patients undergoing renal transplantation
- Apply strategies to improve adherence to treatment regimens following renal transplantation

### Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER<sup>®</sup> website by 12 noon Eastern Time by Monday, June 7, 2021. To access these materials, please visit **https://www.gotoper.com/go/atc2021sot**.

### How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit **https://education.gotoper. com/activity/atc2021sot.** 

The online evaluation and request for credit will be available immediately following the program and will remain available until September 7, 2021.

### Accreditation/Designation of Credit

Physicians' Education Resource<sup>®</sup>, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource<sup>®</sup>, LLC designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Acknowledgment of Commercial Support**

This activity is supported by an educational grant from Sanofi US.

Thank you for attending Let's Get "Real": Minimizing Allograft Rejection in Renal Transplantation – Applying the Evidence to Real-World Scenarios!

To register for upcoming accredited CE live activity or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER<sup>®</sup> accredited CE activities.

## **Activity Overview**

## Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource<sup>®</sup>, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose\*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau
Rita R. Alloway, PharmD	Novartis, Amgen, GSK, Sanofi,BMS, Hookipa, Veloxis, Nobelpharma, Allovir	Veloxis	Veloxis, Sanofi
Daniel Brennan, MD	Allovir, Amplyx, CareDx, Natera	CareDx, Hansa, Medeor, Sanofi, Veloxis	CareDx, Veloxis
E. Steve Woodle, MD	Novartis, Amgen, Bristol Myers Squibb, Veloris	Novartis	Sanofi

#### \*Information accurate at time of posting

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

### **Off-Label Disclosure and Disclaimer**

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER<sup>®</sup> or any of the companies that provided commercial support for this activity.

## Faculty

#### **Program Chair**



### Daniel Brennan, MD

Medical Director, Comprehensive Transplant Center Professor of Medicine Johns Hopkins Medicine Baltimore, MD

#### Faculty



**Rita R. Alloway, PharmD** Research Professor University of Cincinnati College of Medicine Cincinnati, OH



E. Steve Woodle, MD William A. Altemeier Chair in Surgery Professor Director of Solid Organ Transplantation at UC Health Director of Israel Penn Center for Transplant Oncology University of Cincinnati College of Medicine Cincinnati, OH

# **EVOLVING APPROACHES** in Pain Management

**REGIONAL SERIES** 

## SATURDAY, JUNE 26, 2021 | TAMPA, FL

## Apply new alternatives in pain management to patient therapy

#### HOT TOPICS THIS YEAR

- Incorporating alternative treatments into migraine management
- The most effective nonpharmacologic therapies for osteoarthritis
- The evolving role of stem cell therapy for pain management
- Approaching recommendations of cannabis to treat patients for pain
- Genetic testing for opioid pain management

#### **BENEFITS OF ATTENDING**

- Learn about innovative new approaches and apply the latest breakthroughs in pain management
- Network with top minds pain management via our custom, interactive platform to gain valuable insights and evidence-based strategies
- Gain the latest insights and clinical data from world renowned faculty
- Ability to submit questions and participate in expert discussions via our custom, interactive platform



## Jeff Gudin, MD

Attending Physician Department of Anesthesiology Pain Management and Wellness Center Englewood Hospital and Medical Center Englewood, NJ Chief Medical Officer Interventional Pain Institute Baltimore, MD



#### Maneesh Sharma, MD Chief Medical Officer Interventional Pain Institute

Baltimore, MD

#### SAFETY PRECAUTIONS/PERSONAL ACCOUNTABILITY COMMITMENT

By attending this Physicians' Education Resource, LLC's ("PER") program, you agree to abide by and engage in certain health- and safety-beneficial conduct while attending the event, including providing proof at check-in of being 2 weeks removed from receiving a full COVID-19 viral test taken no more than 3 days before the program.

For information on the specific safety precautions that will be in place, please visit <u>event.gotoper.com/AltPainTampa</u> and click on Health & Safety Precautions.



To register, visit

event.gotoper.com/EvolvePainTampa